High Quality API Powder Gefitinib Hydrochloride

Model NO.: Pharmacopoeial grade
Product Name: Gefitinib HCl
Payment: T/T, L/C, Western Union, Moneygram
Delivery Time: 7 Days
Trademark: Biocar
Transport Package: Aluminum Foil Bags or Fiber Drum
Specification: SGS
Origin: Wuhan, Hubei, China
HS Code: 0000000000
Model NO.: Pharmacopoeial grade
Product Name: Gefitinib HCl
Payment: T/T, L/C, Western Union, Moneygram
Delivery Time: 7 Days
Trademark: Biocar
Transport Package: Aluminum Foil Bags or Fiber Drum
Specification: SGS
Origin: Wuhan, Hubei, China
HS Code: 0000000000
Chemical Information
 
Product Name Gefitinib hydrochloride
Molecular Formula C22H25Cl2FN4O3
Molecular Weight 483.36
Storage Store at -20°C
Targets VEGFR-1/2/3        PDGFRβ              RET 
IC50 22/4/5.2nM            39nM                35nM

Description
The EGFR is a Mr 170,000 transmembrane glycoprotein with an external binding domain and an intracellular tyrosine kinase domain. Gefitinib (ZD-1839, Iressa) is an Epidermal Growth Factor Receptor-selective Tyrosine Kinase Inhibitor.
Gefitinib inhibited colony formation in soft agar in a dose dependent manner in all cancer cell lines. However, treatment with higher doses resulted in a 2-4-fold increases in apoptosis. Dose-dependent supra-additive increase in growth inhibition was observed when cancer cells were treated with totoxic drugs and Gefitinib. The combined treatment markedly enhanced apoptotic cell death induced by single agent treatment.
Gefitinib treatment of nude mice bearing established human GEO colon cancer xenografts revealed a reversible dose-dependent inhibition of tumor growth because GEO tumors resumed the growth rate of controls at the end of the treatment.

Dosage 
Administration of a 250-mg dose of gefitinib as a dispersion preparation by drink or nasogastric tube achieved a systemic exposure to gefitinib that was consistent with that achieved when gefitinib was administered as a whole tablet. No evidence of tolerability problems associated with the routes of administration studied was observed in these healthy volunteers. 



  Chemical Information
 
Product Name Gefitinib hydrochloride
Molecular Formula C22H25Cl2FN4O3
Molecular Weight 483.36
Storage Store at -20°C
Targets VEGFR-1/2/3        PDGFRβ              RET 
IC50 22/4/5.2nM            39nM                35nM

Description
The EGFR is a Mr 170,000 transmembrane glycoprotein with an external binding domain and an intracellular tyrosine kinase domain. Gefitinib (ZD-1839, Iressa) is an Epidermal Growth Factor Receptor-selective Tyrosine Kinase Inhibitor.
Gefitinib inhibited colony formation in soft agar in a dose dependent manner in all cancer cell lines. However, treatment with higher doses resulted in a 2-4-fold increases in apoptosis. Dose-dependent supra-additive increase in growth inhibition was observed when cancer cells were treated with totoxic drugs and Gefitinib. The combined treatment markedly enhanced apoptotic cell death induced by single agent treatment.
Gefitinib treatment of nude mice bearing established human GEO colon cancer xenografts revealed a reversible dose-dependent inhibition of tumor growth because GEO tumors resumed the growth rate of controls at the end of the treatment.

Dosage 
Administration of a 250-mg dose of gefitinib as a dispersion preparation by drink or nasogastric tube achieved a systemic exposure to gefitinib that was consistent with that achieved when gefitinib was administered as a whole tablet. No evidence of tolerability problems associated with the routes of administration studied was observed in these healthy volunteers. 



Â